While traditional models discount science risk, we believe operational reliability is the greater determinant of value. Our proprietary analytics evaluate trial design and execution quality across hundreds of programs — uncovering opportunities markets systematically overlook.

We invest selectively in small- to mid-cap biopharma where pivotal trials decide outcomes. Our concentrated long/short portfolio is designed to capture asymmetric valuation moves around clinical catalysts.